ASH 2018 | CAR-T and ibrutinib in combination: a promising treatment for CLL
Lydia Scarfò
Lydia Scarfò, MD, of the Vita-Salute San Raffaele University, Milan, Italy, describes the new challenge of chronic lymphocytic leukemia (CLL) patients relapsing with novel agents. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Scarfò discusses how the use of CAR T-cell therapy is promising in terms of disease control and response, with improved efficacy when combined with ibrutinib, and therefore could be a mainstay in future therapy for CLL.
Similar topics
Related videos

Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery

Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill

An exciting era for CAR T-cell therapy
Mohamad Mohty

Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno

JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
More from Lydia Scarfò